Your own blood as medicine — the German tradition of immune self-regulation.
Quick answer
Autohemotherapy is a German complementary medical procedure reinjecting the patient''s own blood — sometimes mixed with ozone or homeopathic preparations — to modulate immune function. Mainstream in German Heilpraktiker practice, it is restricted in many other jurisdictions.
What Autohemotherapy is commonly used for
Vidi · AI guide
Compare Autohemotherapy with other supportive approaches and get questions to bring to a practitioner.
Gyfts is educational and cannot diagnose or replace care from a qualified professional.
Background
Autohemotherapy has roots in early 20th-century European medicine. The practice of reinjecting the patient''s own blood was documented as early as 1913 by Gruber. It became a standard complementary procedure in German naturopathic medicine (Heilpraktiker practice) and was widely used by German physicians through the mid-20th century. Ozone autohemotherapy was developed in the 1950s–1960s, primarily in Germany and Italy. The technique remains mainstream in German Heilpraktiker practice and is used by some physicians in Austria, Switzerland, and Latin American countries. It has been largely abandoned in mainstream English-speaking medicine due to lack of controlled evidence and regulatory concerns. The German Society for Ozone/Oxygen Therapy maintains clinical guidelines for ozone-based variants.
The practice
A small volume (2–10ml) of venous blood is drawn and immediately reinjected intramuscularly (usually into the gluteal muscle). Variants include: major ozone autohemotherapy (blood mixed with medical-grade ozone before reinjection), minor autohemotherapy (smaller volume, subcutaneous), UV blood irradiation (blood exposed to ultraviolet light before return), and potentised autohemotherapy (blood processed homeopathically). The proposed mechanism is that reintroduced blood components — particularly altered proteins and cellular debris — trigger a non-specific immune stimulation, analogous to an autovaccine effect. This is proposed to modulate chronic inflammatory conditions, allergies, and immune deficiency.
A session takes 15–30 minutes. The physician draws 2–10ml of venous blood and reinjects it intramuscularly. For ozone autohemotherapy, drawn blood is mixed with medical ozone in a closed system before reinjection. Sessions are typically performed 1–2 times per week for 6–12 sessions. Mild injection site soreness and occasionally a brief fever response are expected.
Mechanisms
The biological and psychological processes proposed to underlie how Autohemotherapy is thought to work.
Reintroduced blood components are proposed to trigger an autovaccine-like immune response, modulating chronic inflammatory and immune-deficient states.
In ozone autohemotherapy, medical ozone mixed with blood produces reactive oxygen species proposed to enhance immune cell activity and improve oxygen utilisation.
Evidence Assessment
Evidence is very limited. A small number of German-language observational studies and case reports document immune parameter changes following autohemotherapy. Ozone autohemotherapy has been studied more than the basic technique, with some controlled trials for peripheral arterial disease and chronic hepatitis published in European journals. However, systematic reviews have concluded that the evidence is insufficient to support clinical recommendations. The theoretical immune modulation mechanism is plausible but not demonstrated in adequately powered trials. Safety concerns include infection risk from blood handling and injection site reactions.
Evidence varies by condition and individual response. This information is for educational purposes only and does not constitute medical advice.
Questions
Suitability
Individuals with chronic recurrent infections or immune dysregulation seeking complementary approaches. Those in German-speaking countries where the practice is regulated and mainstream. Patients of Heilpraktiker or integrative physicians with training in the technique.
Those with blood-borne infections (HIV, hepatitis). People with bleeding disorders or on anticoagulants. Individuals with needle phobia. Pregnant women. Those in jurisdictions where the practice is prohibited. People seeking evidence-based first-line immune treatment.
Based on clinical use and available research. Evidence varies by condition and individual response.
These conditions have insufficient or varying evidence. Autohemotherapy may be explored alongside conventional care at practitioner discretion.
Non-specific immune stimulation proposed to address immune dysregulation contributing to chronic fatigue.
Immune modulation may support inflammatory pain conditions within a naturopathic framework.
Ozone autohemotherapy variant proposed for chronic inflammatory pain conditions.
Related
Based on the conditions Autohemotherapy is used to support, practitioners commonly work with people experiencing these symptoms: